Precigen, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen Sabzevari
- Full Time Employees
- 160
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 20374 Seneca Meadows Parkway Germantown MD United States 20876
- IPO Date
- Aug 8, 2013
- CIK
- 0001356090
- Website
- precigen.com
- Similar Companies
- Business
- Precigen, Inc. (Nasdaq: PGEN) is a clinical-stage biopharmaceutical company that develops gene and cell therapies using proprietary precision technologies to target diseases in immuno-oncology, autoimmune disorders, and infectious diseases; its core platforms include the AdenoVerse immunotherapy platform, which employs proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and the UltraCAR-T platform, which provides controllable chimeric antigen receptor T-cell therapies for hematological malignancies and solid tumors. The company offers PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved AdenoVerse gene therapy for recurrent respiratory papillomatosis (RRP) in adults; additional pipeline candidates such as PRGN-2009 in combination with pembrolizumab for HPV-associated cancers, PRGN-3005 for ovarian cancer, PRGN-3006 for acute myeloid leukemia and myelodysplastic syndromes, and PRGN-3007 for hematological and solid tumors; and services through its Exemplar subsidiary, which develops research models for healthcare applications including the UltraPorator electroporation device. Founded in 1998 and headquartered in Germantown, Maryland, Precigen operates primarily in the United States with a focus on advancing therapies from discovery through commercialization. Recent developments include the FDA approval of PAPZIMEOS in 2025, a $125 million non-dilutive credit facility with Pharmakon Advisors in September 2025 featuring a $100 million initial tranche to support U.S. commercialization of PAPZIMEOS and international expansion, and a $79 million private placement of preferred stock in December 2024 extending cash runway into 2026.
Company News
Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
What Precigen (PGEN) Said on Its Q3 Earnings Call
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
Precigen, Inc. $PGEN Stock Sold by Iridian Asset Management LLC CT
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen (NASDAQ:PGEN) Hits New 1-Year High – Time to Buy?
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?